RPG Life Sciences Approves ₹243 Crore API Subsidiary Investment And Acquisition

29 July 2026

RPG Life Sciences Ltd.

Bulk drug intermediates supplier for complex API ingredients

Recent Events

RPG Life Sciences Carves Out API Business, Raises ₹243 Crore From InvAscent

RPG Life Sciences Approves Rs 243 Crore Investment, Actis Generics Acquisition

RPG Life Sciences Board Approves ₹243 Crore Investment And Actis Generics Acquisition

Get features of